/ALUR
ALUR Stock - Allurion Technologies Inc.
Healthcare|Medical - DevicesNYSE
$1.47-2.00%
$0.03 (-2.00%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+70.1%upside
Target: $2.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALUR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.46 – $1.48
TARGET (TP)$2.50
STOP LOSS$1.35
RISK/REWARD1:8.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.49
52W High$16.81
52W Low$1.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $32.11M | $53.47M | $64.21M | $38.24M | N/A |
| Gross Profit | $21.50M | $41.50M | $50.73M | $29.19M | N/A |
| Gross Margin | 67.0% | 77.6% | 79.0% | 76.3% | N/A |
| Operating Income | $-50,198,000 | $-79,078,000 | $-32,010,000 | $-12,501,000 | $-5,169 |
| Net Income | $-26,148,000 | $-80,607,000 | $-37,744,000 | $-12,386,000 | $-5,169 |
| Net Margin | -81.4% | -150.8% | -58.8% | -32.4% | N/A |
| EPS | $-11.64 | $-57.83 | $-37.75 | $-0.25 | $0.00 |
Company Overview
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$3
Average Target
↑ 104.1% Upside
Now
$2
Low
$3
Average
$5
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2024 | Chardan Capital Markets | Downgrade | Neutral | - |
| October 2nd 2024 | TD Cowen | Initiation | Buy | $2 |
| September 6th 2024 | ROTH MKM | Initiation | Buy | $2 |
| February 9th 2024 | Jefferies | Initiation | Buy | $5 |
Earnings History & Surprises
ALURBeat Rate
63%
Last 8 quarters
Avg Surprise
+153.5%
EPS vs Estimate
Beats / Misses
5/3
Last 12 quarters
Latest EPS
$-1.18
Q4 2025
EPS Surprise History
Q1 24
-23.5%
$-15.75vs$-12.75
Q2 24
+1016.7%
$2.75vs$-0.30
Q3 24
+204.2%
$0.25vs$-0.24
Q4 24
+17.6%
$-3.50vs$-4.25
Q1 25
-40.0%
$-7.00vs$-5.00
Q2 25
+128.1%
$0.43vs$-1.53
Q3 25
+12.3%
$-0.57vs$-0.65
Q4 25
-87.3%
$-1.18vs$-0.63
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.63 | $-1.18 | -87.3% | ✗ MISS |
Q3 2025 | Aug 19, 2025 | $-0.65 | $-0.57 | +12.3% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-1.53 | $0.43 | +128.1% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-5.00 | $-7.00 | -40.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-4.25 | $-3.50 | +17.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.24 | $0.25 | +204.2% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.30 | $2.75 | +1016.7% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-12.75 | $-15.75 | -23.5% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | — | $-15.25 | — | — |
Q4 2023 | Oct 20, 2023 | — | $-2.17 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.58 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.11 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.29 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.12 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.14 | — | — |
Q4 2021 | Dec 30, 2021 | — | $0.02 | — | — |
Q3 2021 | Sep 29, 2021 | — | $0.18 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-0.10 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.05 | — | — |
Latest News
Allurion Technologies Reports Initial Results On Combination Of Allurion Program With Low-Dose Tirzepatide Therapy To Optimize Muscle Mass And GLP-1 Adherence
📈 PositiveBenzinga•Nov 25, 2025, 02:28 PM
Allurion Smart Capsule Combined With Lifestyle Intervention Achieves 20% Average Weight Loss In 36 Weeks, Outperforming Lifestyle Intervention Alone, Study In 'Obesity Surgery' Shows
📈 PositiveBenzinga•Nov 20, 2025, 02:08 PM
Chardan Capital Maintains Neutral on Allurion Technologies, Maintains $2.5 Price Target
➖ NeutralBenzinga•Nov 20, 2025, 12:25 PM
Allurion Technologies Announces Strategic Distribution Partnership With ProSurg Medical To Establish New Standard Of Care Focused On Metabolically Healthy Weight Loss
📈 PositiveBenzinga•Nov 18, 2025, 02:09 PM
Public Investment Fund Maintains Stake In Allurion Technologies Inc At 1,148,436 Shares.
➖ NeutralBenzinga•Nov 14, 2025, 03:49 PM•Also:
Allurion Technologies Q3 Adj. EPS $(1.18) Misses $(1.17) Estimate, Sales $2.658M Beat $2.350M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 01:03 PM
Allurion Technologies Passes Critical Milestones In U.S. FDA's Pre-Market Approval Process For Allurion Smart Capsule; Company To Exchange All Outstanding Debt, Obligations For Shares Of Newly Created Series B Convertible Preferred Stock
📈 PositiveBenzinga•Nov 11, 2025, 01:51 PM
Allurion Highlights Peer-Reviewed Publication On Consecutive Use Of Allurion Smart Capsule
📈 PositiveBenzinga•Oct 7, 2025, 12:09 PM
Frequently Asked Questions about ALUR
What is ALUR's current stock price?
Allurion Technologies Inc. (ALUR) is currently trading at $1.47 per share. The stock has moved -2.00% today.
What is the analyst price target for ALUR?
The average analyst price target for ALUR is $2.50, based on 1 analyst.
What sector is Allurion Technologies Inc. in?
Allurion Technologies Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is ALUR's market cap?
Allurion Technologies Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ALUR pay dividends?
No, Allurion Technologies Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
AEMD
Aethlon Medical, Inc.
$2.86
Mkt Cap: $0.0B
COCH
Envoy Medical, Inc.
$0.73
Mkt Cap: $0.0B
CODX
Co-Diagnostics, Inc.
$0.26
Mkt Cap: $0.0B
ERNA
Ernexa Therapeutics Inc.
$1.31
Mkt Cap: $0.0B
LFWD
Lifeward Ltd.
$0.65
Mkt Cap: $0.0B
NVNO
enVVeno Medical Corporation
$0.32
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.09
Mkt Cap: $0.0B
VVOS
Vivos Therapeutics, Inc.
$1.97
Mkt Cap: $0.0B
XAIR
Beyond Air, Inc.
$0.91
Mkt Cap: $0.0B
Explore stocks similar to ALUR for comparison